Ancona VAE, Lago AA, Parada TMG, González PM

Language: Spanish
References: 18
Page: 535-543
PDF size: 525.38 Kb.

ABSTRACT

Background: Calcio-antagonists are antihypertensive drugs of proven efficacy and safety, with response rates in monotherapy between 55 and 84%. They belong to a chemico-pharmacological and therapeutically heterogeneous group, and their primary effect is vasodilation.
Objective: Determine the efficacy of amlodipine besylate as monotherapy in a group of patients with diagnosis of arterial hypertension, evaluate cardiovascular risk factors.
Patients and method: A multicentric, longitudinal, open label, observational study, in Mexican population in real-life conditions, in phase IV, with AHT diagnosis. I-II.
Results: 3086 subjects were enrolled with 1060 doctors in 51 cities in Mexico. The average age was 54.2 years SD. 54.2. Mean BMI. 29.8 SD. 4.8; 43.2% male and 56.8% female. Baseline systolic pressure, mean 157.3 SD. 13.9 reduction of AP at two weeks was -15.7 and at 4 weeks -27.6 SD. 15.0. Diastolic pressure: baseline 96.7 SD 6.9 at two weeks baseline reduction -9.4 at weeks -15.8 SD. 8.5. Other cardiovascular risk factors were analyzed independently, each of which was significant for blood pressure.
Conclusions: Individual analysis of AP figures proved the efficacy of amlodipine management in short-term control of blood pressure figures with reduction of cardiovascular risk. Best response in older age groups. Also, the interrelationship of all risk factors with blood pressure figures.

REFERENCES

1. Velazquez MO, Rosas PM, et al. Arterial hypertension in Mexico: results of the National Health Survey 2000. Arch Cardiol Mex 2002;72(1):71-84.

2. Rosas P M, Lara EA, et al. National-Resurvey of Arterial Hypertension (RENAHA). Mexican consolidation of the vascular cardiovascular risk factors. National follow-up cohort. Arch Cardiol Mex 2005;75(1):96-111.

3. Norma Oficial Mexicana NOM-030-SSA2-1999 para la prevención, tratamiento y control de la hipertensión arterial.

4. Taylor SH, Chen MF, et al. Efficacy and tolerability of Amlodipine in the general practice treatment of essential hypertension in an Asian multinational population. Clin Drug Investig 1998;16(3):177-185.

5. The STONE study (Shanghai Trial of Hypertension in the Elderly): A meeting report. Cardiovascular Drugs and Therapy 1996;10(4):467-468.

6. Aram V, Bakris GL, Black HR, et al. Seven Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). JAMA 2003;289(19):2560-2572.

7. Guidelines for the management of arterial hypertension. European Society of Hypertension, European Society of Cardiology. J Hypertens 2003;21:1011-1053.

8. 2003 World Health Organization (WHO)/ international Society of hypertension (ISH) statement on management of hypertension. J of Hypertens 2003;21(11): 1983-1992.

9. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent Herat attack trail (ALLHAT). J of Clin Hypertens 2002; 4(VI):393-404.

10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensine-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288(23):2981-2997.

11. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290(2):199-206.

12. Staessen JA, Wang Ji-Guang, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview update until March 2003. J of Hypertens 2003;21:1055-1076.

13. McMahom S, Cutler J, Fagard R, et al. Effects of ACE inhibitors, calcium antagonist and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;356:1955-1964.

14. Carrillo C, Cárdenas T. Hipertensión arterial sistémica. Diagnóstico, tratamiento y prevención. Bol Prac Med Efect. Instituto Nacional de Salud Pública, Oct 2006.

15. Arellano F, Jasso-Soto ME. Tratamiento de la hipertensión arterial sistémica. Archi Card Méx 2002.

16. Institute for Clinical Systems Improvement (ICSI). Hypertension diagnosis and treatment. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006(53).

17. Puente-Ramon M, et al. Hipertensión arterial. Guías Clínicas 2004;4(34).

18. Guías Clínicas de Hipertensión Arterial. I – IX. Hipertensión 2002; 19 Suppl 3:56-9.